Insulin Price Cuts Could End Up Making Money for US Drugmakers
From Bloomberg, In Print — Mar 14th, 2023
Even with insulin prices cut by up to 75% under U.S. government pressure, major manufacturers like Novo Nordisk and Eli Lilly could still see profits rise. Spencer Perlman, Director of Healthcare Research at Veda Partners, notes that Lilly could avoid $430 million per year in new Medicaid rebates, boosting annual profits by more than $85 million.
Henrietta Treyz, Director of Economic Policy at Veda Partners, adds that such maneuvers highlight how regulatory changes can create unexpected financial incentives for large pharmaceutical companies.
This excerpt and any accompanying media (including audio, video, or images) are shared under the principles of fair use, for informational and archival purposes only. All rights remain with the original publisher.